Clinical Trials Logo

Soft Tissue Sarcomas clinical trials

View clinical trials related to Soft Tissue Sarcomas.

Filter by:

NCT ID: NCT02575066 Terminated - Sarcoma Clinical Trials

Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients

PASART-2
Start date: March 17, 2016
Phase: Phase 2
Study type: Interventional

Radiotherapy (RT) alone is able to induce a clinically significant effect with a variable pathologic response (a pathological complete remission, pCR, defined as ≥ 95%, or ≤ 5% remaining visible tumour cells) in only about 10% of cases. A prior phase I study (PASART-1; NCT01985295) suggested that 25 x 2 Gy preoperative RT in combination with once daily 800mg oral pazopanib is feasible, while inducing tissue replacing tumor that can consist of fibrosis and necrosis in 40% of thus treated patients. During this study, the interim analysis showed that the combination treatment of preoperative radiation with orally pazopanib is more effective than was anticipated. For this reason, the pazopanib dose of 800 mg once daily is maintained but the RT dose is reduced to 18x2Gy instead of 25x2Gy. Predominant aim of this RT dose reduction is lowering the wound complication risk after preoperative radiotherapy.

NCT ID: NCT02536183 Terminated - Solid Tumors Clinical Trials

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

Start date: October 2016
Phase: Phase 1
Study type: Interventional

This study is looking to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lyso-thermosensitive liposomal doxorubicin (LTLD) administered in combination with MR-HIFU in children with relapsed/refractory solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, and germ cell tumors.

NCT ID: NCT01830153 Completed - Clinical trials for Soft Tissue Sarcomas

RAD001 in Advanced Sarcoma

Start date: April 2010
Phase: Phase 2
Study type: Interventional

This trial intends to test the efficacy and safety of RAD001 in patients with advanced sarcoma who failed to conventional chemotherapy.

NCT ID: NCT00881595 Withdrawn - Clinical trials for Soft Tissue Sarcomas

Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas

SA02
Start date: February 2009
Phase: Phase 2
Study type: Interventional

The goal of this study is to evaluate the effects of temozolomide and radiation combination in the treatment intended of soft tissue sarcomas. This study will also look at the tumor tissue that was removed during your initial biopsy and your final surgery for information that may help to treat soft tissue sarcoma in the future. In addition the investigators will examine a sample of your normal tissue (optional) from the inside of your mouth/cheek (to compare it to your tumor tissue) before starting treatment.

NCT ID: NCT00687778 Recruiting - Lung Cancer Clinical Trials

11C-Acetate PET/CT Non-FDG-Avid Tumors

Start date: May 2008
Phase: N/A
Study type: Observational

F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor. There are various types of human malignancies, which are not taking FDG in access. In these cases FDG is not a sensitive tracer of imaging. In search for other tumor PET tracers, C11-Acetate has been shown recently in a few early studies to have a potential value in imaging of non-FDG-avid tumors. The purpose of the current study is to assess the role of 11C-acetate PET in various tumors, which often are not detected by 18F-FDG and were not widely assessed until now.

NCT ID: NCT00423254 Completed - Gastric Cancer Clinical Trials

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.

NCT ID: NCT00385203 Completed - Clinical trials for Gastrointestinal Stromal Tumors

The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).

Start date: September 2006
Phase: Phase 2
Study type: Interventional

To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy) and also in patients with metastatic Soft Tissue Sarcoma (STS) resistant to standard therapy.

NCT ID: NCT00276302 Completed - Clinical trials for Gastrointestinal Stromal Tumors

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Start date: December 2005
Phase: Phase 1
Study type: Interventional

The primary objectives of the study are: - Determine the safety and maximum tolerated dose (MTD) of IPI-504 in GIST and STS patients who have failed prior therapies - Recommend a dose for subsequent studies of IPI-504